Università degli Studi di Padova

Padua Research Archive - Institutional Repository

The molecular landscape of colitis-associated carcinogenesis

Original Citation:

Availability:

This version is available at: 11577/3218452 since: 2017-02-06T15:38:10Z

Publisher:

Elsevier B.V.

Published version:

DOI: 10.1016/j.dld.2016.12.011

Terms of use:

Open Access

This article is made available under terms and conditions applicable to Open Access Guidelines, as described at <http://www.unipd.it/download/file/fid/55401> (Italian only)

(Article begins on next page)

Alimentary Tract

The molecular landscape of colitis-associated carcinogenesis

Deborah Saraggi^{a,1}, Matteo Fassan^{a,1}, Claudia Mescoli^e, Marco Scarpa^b, Nicola Valeri^{c,d}, Andrea Michielan^e, Renata D'Incá^e, Massimo Rugge^{a,*}

^a Department of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, Padua, Italy

^b Istituto Oncologico Veneto, IOV-IRCCS, Surgical Oncology Unit, Padua, Italy

^c Department of Molecular Pathology, The Institute of Cancer Research, London, UK

^d Department of Medicine, The Royal Marsden NHS Trust, London, UK

^e Department of Surgical Oncology and Gastroenterology (DiSCOG), Gastroenterology Unit, University of Padua, Padua, Italy

ARTICLE INFO

Article history:

Received 17 November 2016

Accepted 9 December 2016

Available online xxx

Keywords:

Biomarkers

Colitis

Dysplasia

IBD

Molecular pathology

ABSTRACT

In spite of the well-established histopathological phenotyping of IBD-associated preneoplastic and neoplastic lesions, their molecular landscape remains to be fully elucidated. Several studies have pinpointed the initiating role of longstanding/relapsing inflammatory insult on the intestinal mucosa, with the activation of different pro-inflammatory cytokines (TNF- α , IL-6, IL-10, IFN- γ), chemokines and metabolites of arachidonic acid resulting in the activation of key transcription factors such as NF- κ B. Longstanding inflammation may also modify the intestinal microbiota, prompting the overgrowth of genotoxic microorganisms, which may act as further cancer promoters. Most of the molecular dysregulation occurring in sporadic colorectal carcinogenesis is documented in colitis-associated adenocarcinoma too, but marked differences have been established in both their timing and prevalence. Unlike sporadic cancers, *TP53* alterations occur early in IBD-related carcinogenesis, while *APC* dysregulation emerges mainly in the most advanced stages of the oncogenic cascade. From the therapeutic standpoint, colitis-associated cancers are associated with a lower prevalence of *KRAS* mutations than the sporadic variant. Epigenetic changes, including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs, are significantly involved in colitis-associated cancer development and progression. The focus now is on identifying diagnostic and prognostic biomarkers, with a view to ultimately designing patient-tailored therapies.

© 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

1. Introduction

Sporadic colorectal carcinogenesis comprises a well-established sequence of phenotypic changes and molecular derangements [1]. Among non-syndromic colorectal cancers (CRC), on the other hand, colitis-associated cancer (CAC) is a particular entity with its own natural history, precancerous phenotypes, and molecular profile [2].

In both Crohn's disease (CD) and ulcerative colitis (UC), the cumulative risk of cancer ranges between 3% and 5% [3–5]. In single patients, the CAC risk increases along with the duration and severity of the inflammatory disease, and rises further in patients with familial CRC and/or concomitant primary sclerosing cholangitis [6–13].

The natural history of CAC prompts the recommendation for follow-up strategies that are consistently based on endoscopic surveillance coupled with appropriate (extensive) biopsy sampling [14,15]. The histological detection of precancerous lesions (*i.e.* dysplasia [synonym: intra-epithelial neoplasia; IEN]) is discriminatory in the choice of clinical strategy for the purpose of secondary cancer prevention [16,17]. Colitis-associated dysplasia frequently occurs in the form of patchy, flat lesions that may easily be overlooked, even with latest-generation high-definition endoscopy [2,18].

This clinical background means that priority goes to efforts to identify reliable biomarkers of a high cancer risk and/or early neoplastic transformation [19,20]. Such efforts come up against three main difficulties, however: (i) the complexity of the genetic background behind IBD-associated carcinogenesis; (ii) the confounding interference of the gut microbiota in colitis-associated carcinogenesis; and (iii) the characteristics of biopsy samples available for translational research purposes. In clinical practice, IBD biopsy samples are obtained mainly for diagnostic purposes, and tend to consist of formalin-fixed, paraffin-embedded (FFPE) specimens,

* Corresponding author at: Department of Medicine DIMED; University of Padua, via Gabellini 61, 35121 Padova, Italy. Fax: +39 049 8272277.

E-mail address: massimo.rugge@unipd.it (M. Rugge).

¹ Contributed equally.

which are considered sub-optimal for use in downstream molecular biology procedures [1].

This review aims to provide an up-to-date overview of the peculiar histology and molecular background of IBD-associated carcinogenesis.

2. Histology of dysplasia and colitis-associated cancer

In IBD patients, dysplasia is the most reliable marker of a higher risk of malignancy [2,21–23]. The accuracy of the endoscopic inspection and the appropriateness of the biopsy sampling protocol both significantly affect the likelihood of dysplasia being detected histologically, which also depends on the pathologist's experience [24–27].

Grossly, IBD-associated dysplasia may occur as flat or raised (polypoid) mucosal lesions [23,28–30]. While the latter are generally detectable on “traditional” endoscopy, the reliable assessment of flat lesions demands elective endoscopy experience and high-performance instruments. Even if such conditions are met, IBD-associated dysplasia is most frequently encountered in randomly obtained biopsy samples [2].

Depending on their histological phenotype, polypoid alterations can be divided into two sub-categories: (i) dysplasia-associated lesions or masses (DALM); and (ii) adenoma-like lesions [23]. The definition of DALM includes irregular bumps, plaques, velvety patches, nodules, wart-like thickenings, stricturing lesions and broad-based masses. These lesions can easily be masked by gross inflammatory abnormalities, and they are not usually amenable to removal using routine endoscopic methods [14,15]. On the other hand, adenoma-like lesions (both sessile, and pedunculated) are endoscopically indistinguishable from sporadic colorectal cancer, and are easy to remove endoscopically [2,31]. The distinction between DALM and adenoma-like dysplasia has far from negligible clinical consequences because polypoid lesions only require endoscopic resection, whereas the frequent concomitance of DALM with cancer warrants prophylactic proctocolectomy [27].

As for the histological assessment, the ECCO/ESP Consensus panel recommends that histological diagnoses be confirmed by a “GI-dedicated” pathologist [27]. Despite its well-established definition, the histological recognition and grading of dysplasia in this setting suffers from a significant inter-observer variability. Distinguishing between low-grade (LG) and high-grade (HG) lesions entails a different patient management due to the different prevalence of synchronous cancers detected in dysplasia patients undergoing proctocolectomy (LG and HG dysplasia are associated with synchronous cancer in 3% and 29% of cases, respectively) [32].

Invasive adenocarcinoma is identified from the “invasive” spreading of neoplastic cells beyond the native structure of the colonic glands. Compared with sporadic CRCs, IBD-associated cancers tend to be multifocal, more often mucinous, frequently including a signet ring cell component, and featuring a higher histological grade (Fig. 1) [18,29,33].

3. Molecular landscapes of colitis-associated cancers

3.1. The pathogenic role of the inflammatory insult

Colitis-related carcinogenesis is characterized by a cascade of molecular and phenotypic alterations initiated and sustained by (relapsing) inflammation [34,35]. As in other inflammation-related carcinogenic models, so too in the IBD setting, the pathogenic role of longstanding inflammation is supported by two main clinical factors: (i) the risk of CAC increases along with the duration/severity of the disease; and (ii) the introduction of anti-inflammatory

treatment is associated with significant reduction in this cancer risk [25,36–38].

The molecular mechanisms linking longstanding IBD with cancer are gradually becoming less obscure. The long-term persistence of inflammation sustained by granulocytes, plasma cells, lymphocytes, and macrophages results in high levels of pro-inflammatory cytokines (tumor necrosis factor- α [TNF- α], interleukin-6 [IL-6], interleukin-10 [IL-10], interferon- γ [IFN- γ]), chemokines and metabolites of arachidonic acid [39]. This “inflammatory background” leads to the activation of key transcription factors, such as nuclear transcription factor kappaB [NF- κ B], that play a pivotal part in cancer development [29].

Among the pro-inflammatory cytokines, IL-6 in particular promotes proliferation and inhibits apoptosis by activating the JAK/STAT signaling pathway [40,41]. The IL-6-dependent enhancement of human colon cancer cell proliferation *in vitro* is largely mediated by hyperphosphorylation of the transcription factor STAT3 [42,43]. In biopsy samples obtained from active UC coexisting with neoplastic lesions, IL-6 and STAT3 expression in the gut epithelia is significantly higher than in either patients with inactive IBD or non-IBD controls [44]. Matsumoto et al. demonstrated that activation of the IL-6/STAT3 pathway is involved in both the experimental development of ileitis (SAMP1/Yit mice) and in cancer promotion [45].

In IBD, as in other carcinogenic models, several pro-inflammatory cytokines (particularly IL-1 and TNF- α) also significantly enhance the production of cyclo-oxygenase-2 (COX2), an inducible enzyme that interferes with cell proliferation, angiogenesis, and apoptosis. In the IBD setting, COX2 mRNA levels have been found increased in the inflamed mucosa, in dysplastic lesions, and in IBD-associated cancer [46].

Another important mechanism involved in the initiation and/or progression of CAC is oxidative stress of the colon mucosa due to the production and accumulation of reactive oxygen species (ROS), and reactive nitrogen intermediates (RNI) [47]. Stimulated by the pro-inflammatory cytokines, the inflammatory cells produce ROS and RNI, which in turn recruit additional inflammatory cells, generating to a self-promoting pathogenic loop. Oxidative stress is known to be involved in cancer biology because of its ability to damage DNA, and cell lipids and proteins [48,49]. For instance, the lipid peroxidation occurring when ROS and RNI interact with cell membranes gives rise to DNA adducts that frequently involve the TP53 gene [48,49].

3.2. The intestinal microbiota in the carcinogenic cascade

Mounting evidence supports a role for both intestinal microbiota, and innate immune responses in initiating and maintaining colonic mucosa inflammation, and in eventually promoting colon cancer [29].

Gut microbiota imbalance (*i.e.* dysbiosis) is well documented in IBD patients, and dysbiosis is emerging as a key player in the pathogenesis of CAC. A higher prevalence of colon cancers has been documented in rodents colonized with feces obtained from CAC mice than in rodents treated with feces obtained from healthy mice. The demonstration that neither IL-10-deficient mice, nor TCR β /p53 double knockout mice ever develop colon cancer under germfree environmental conditions further supports the interplay between colorectal cancer and gut microbiota [50].

IL-10 is a potent anti-inflammatory cytokine that inhibits NF- κ B signaling [51–53]. IL-10-deficient mice have less diversity in their intestinal bacteria (a situation consistently demonstrated in both human and experimental cancers). In this murine model, gut colonization with either *Escherichia coli* or *Enterococcus faecalis* results in colonic inflammation, but it is noteworthy that only animal colonized by *E. coli* develop inflammation-related colon tumors [54,55].

Fig. 1. Pathological and molecular features of IBD-related and sporadic adenocarcinomas.

3.3. Molecular pathways driving cancer initiation

The major molecular dysregulations involved in sporadic CRCs have been documented in colitis-associated neoplastic lesions too, though the timing and frequency of such molecular alterations in the latter reveal features peculiar to IBD [1]. In CAC, as in sporadic CRC, chromosomal instability (CIN), microsatellite instability (MSI), telomere shortening, and CpG island methylator phenotype (CIMP) are the main causative events behind genetic instability [29,56]. In UC patients, telomere shortening has been documented in mucosa adjacent to dysplasia and cancer, and it has been detected more frequently in patients who subsequently develop cancer [57,58].

In contrast with the late involvement of *TP53* dysregulation in sporadic colon carcinogenesis, seminal mutational profiling and LOH studies addressing IBD-associated oncogenesis have consistently pinpointed *TP53* mutations and *TP53* gene locus loss as early molecular changes already underway in intraepithelial neoplastic lesions [59–65]. *TP53* mutations have also been observed in non-dysplastic UC-affected mucosa, further supporting the early involvement of *TP53* [66]. It is worth adding that mice harboring a germline *TP53* mutation show a prolonged NF- κ B activation and a rapid onset of flat dysplastic lesions that progress to invasive carcinoma in the dextran sulfate sodium (DSS) cancerization model [67].

The *adenomatous polyposis coli* (*APC*) gene is a driver of sporadic colorectal carcinogenesis, being involved in β -catenin regulation, cytoskeleton organization, apoptosis, and cell adhesion [1,68]. *APC* dysregulation is less frequent in IBD-related carcinogenesis, occurring only in advanced phases (if ever), and it has never been associated with non-dysplastic mucosa [63,69–71]. In the setting of IBD, it has been suggested that an enhanced β -catenin signaling could be promoted by the inflammatory micro-environment instead.

KRAS mutations are relatively less common in CAC than in sporadic carcinomas, and this may have therapeutic implications [72,73]. A recent whole-exome sequencing study on 31 IBD-related CRCs demonstrated a low *KRAS* mutation rate, further validating both the low prevalence of *APC* mutations and the high rate of *TP53* mutations [74]. The authors also demonstrated that alterations in *SOX9* and *EP300* (Wnt pathway), *NRG1* (ERBB pathway) and *IL16* (cytokine) genes are frequently involved. Their analysis identified recurrent mutations in the Rho and Rac GTPase network, pointing to a role for non-canonical Wnt signaling in the IBD setting.

3.4. Epigenetic modifications

Epigenetic changes – including DNA methylation, histone modifications, chromatin remodeling and small non-coding microRNAs

– are involved in both the CRC's initiation and the progression [75–78]. Epigenetic silencing in DNA repair genes (such as *hMLH1*, *p16INK4a* and *MGMT*), which results in MSI, has been found in the CAC setting too [79]. MLH1 promoter hypermethylation is less frequent than in sporadic MSI cancers, however, because oxidative stress and ROS might cause MSI even in the absence of defects in the DNA mismatch repair pathway [29]. The CIMP pathway is also seen less often in CAC [80,81].

For the last three decades, microRNAs (miRNAs) have represented the most promising class of diagnostic and prognostic biomarkers. Their stability in biological samples, small size, ability to regulate hundreds of messenger RNAs (mRNAs), and relatively small total number (compared to mRNAs) make miRNAs plausible candidates for monitoring the cancer risk associated with IBD [82–84].

In 2008, a seminal study on miRNA expression in colonic mucosa samples from IBD patients identified a set of 11 miRNAs expressed differently in active UC vis-à-vis normal colonic mucosa [85]. This initial evidence was supported by further studies. Among others, miR-21 and miR-135b emerged as common key oncogenes in both sporadic and IBD-related carcinogenic processes [86,87]. Moreover, thanks to their intrinsic stability in body fluids, measuring circulating miRNA levels in the plasma and serum of IBD patients has shown potential as a tool for enabling an earlier diagnosis and prognosis, and for predicting response to therapy [83,88,89].

4. Conclusions

In spite of our thorough understanding of the phenotypic events occurring in IBD-related carcinogenesis, its molecular profiling has only been partially clarified. No reliable biomarkers are available as yet for prognosticating the cancer risk associated with colitis. The picture is further complicated by the recent acknowledgment of the influence of intestinal dysbiosis, which represents an additional variable in an already puzzling landscape.

There is growing evidence to support the reliability of some IBD-specific molecular markers of cancer risk, but none of them have been validated as yet, and their therapeutic implications (if any) are by no means well established. So is it time to test the reliability of (at least) some of these biomarkers in clinical diagnostic practice? Some of the available evidence seems to suggest that the time has come.

Conflict of interest
None declared.

Financial support

This work was partly supported by a grant from the Italian Association for Cancer Research (AIRC Regional grant 2008 N. 6421).

References

- [1] Fassan M, Baffa R, Kiss A. Advanced precancerous lesions within the GI tract: the molecular background. *Best Practice & Research Clinical Gastroenterology* 2013;27:159–69.
- [2] Mescoli C, Albertoni L, D'Inca R, et al. Dysplasia in inflammatory bowel diseases. *Digestive and Liver Disease* 2013;45:186–94.
- [3] Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001;48:526–35.
- [4] Gillen CD, Walmsley RS, Prior P, et al. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. *Gut* 1994;35:1590–2.
- [5] Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. *Cancer* 2001;91:854–62.
- [6] Tsaitas C, Semertzidou A, Sinakos E. Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. *World Journal of Hepatology* 2014;6:178–87.

- [7] Askling J, Dickman PW, Karlen P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. *Gastroenterology* 2001;120:1356–62.
- [8] Nuako KW, Ahlquist DA, Mahoney DW, et al. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. *Gastroenterology* 1998;115:1079–83.
- [9] Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. *Clinical Gastroenterology and Hepatology* 2012;10:639–45.
- [10] Ekblom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. *The New England Journal of Medicine* 1990;323:1228–33.
- [11] Soderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. *Gastroenterology* 2009;136:1561–7 [quiz 1818–9].
- [12] Brackmann S, Andersen SN, Aamodt G, et al. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. *Scandinavian Journal of Gastroenterology* 2009;44:46–55.
- [13] Jess T, Simonsen J, Jorgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. *Gastroenterology* 2012;143:375–81, e1; [quiz e13–4].
- [14] Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. *Gastroenterology* 2010;138:738–45.
- [15] Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). *Gut* 2010;59:666–89.
- [16] Collins PD, Mpofu C, Watson AJ, et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. *Cochrane Database of Systematic Reviews* 2006;2:CD000279.
- [17] Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. *Gastroenterology* 2006;130:1030–8.
- [18] Zisman TL, Rubin DT. Colorectal cancer and dysplasia in inflammatory bowel disease. *World Journal of Gastroenterology* 2008;14:2662–9.
- [19] Manuc TE, Manuc MM, Diculescu MM. Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets. *Clinical and Experimental Gastroenterology* 2016;9:59–70.
- [20] Boyapati RK, Kalla R, Satsangi J, et al. Biomarkers in search of precision medicine in IBD. *The American Journal of Gastroenterology* 2016;111:1682–90.
- [21] Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. *World Journal of Gastroenterology* 2008;14:378–89.
- [22] Ullman T, Odze R, Farraye FA. Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. *Inflammatory Bowel Diseases* 2009;15:630–8.
- [23] Cornaggia M, Leutner M, Mescoli C, et al. Chronic idiopathic inflammatory bowel diseases: the histology report. *Digestive and Liver Disease* 2011;43(Suppl. 4):S293–303.
- [24] Eaden J, Abrams K, McKay H, et al. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. *The Journal of Pathology* 2001;194:152–7.
- [25] Langner C, Magro F, Driessen A, et al. The histopathological approach to inflammatory bowel disease: a practice guide. *Virchows Archiv* 2014;464:511–27.
- [26] Allende D, Elmessiry M, Hao W, et al. Inter-observer and intra-observer variability in the diagnosis of dysplasia in patients with inflammatory bowel disease: correlation of pathological and endoscopic findings. *Colorectal Disease* 2014;16:710–8 [discussion 718].
- [27] Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. *Journal of Crohn's and Colitis* 2013;7:827–51.
- [28] Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. *Human Pathology* 1983;14:931–68.
- [29] Harpaz N, Ward SC, Mescoli C, et al. Precancerous lesions in inflammatory bowel disease. *Best Practice & Research Clinical Gastroenterology* 2013;27:257–67.
- [30] Bressenot A, Cahn V, Danese S, et al. Microscopic features of colorectal neoplasia in inflammatory bowel diseases. *World Journal of Gastroenterology* 2014;20:3164–72.
- [31] Engelsing M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. *Gastroenterology* 1999;117:1288–94 [discussion 1488–91].
- [32] Kiran RP, Ahmed Ali U, Nisar PJ, et al. Risk and location of cancer in patients with preoperative colitis-associated dysplasia undergoing proctocolectomy. *Annals of Surgery* 2014;259:302–9.
- [33] Delaunoy T, Limburg PJ, Goldberg RM, et al. Colorectal cancer prognosis among patients with inflammatory bowel disease. *Clinical Gastroenterology and Hepatology* 2006;4:335–42.
- [34] Ullman T, Itzkowitz SH. Intestinal inflammation and cancer. *Gastroenterology* 2011;140:1807–16.
- [35] Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. *American Journal of Physiology–Gastrointestinal and Liver Physiology* 2004;287:G7–17.
- [36] Matula S, Croog V, Itzkowitz S, et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. *Clinical Gastroenterology and Hepatology* 2005;3:1015–21.

- [37] Eaden J. Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. *Alimentary Pharmacology & Therapeutics* 2003;18(Suppl. 2):15–21.
- [38] Nieminen U, Jussila A, Nordling S, et al. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data. *International Journal of Cancer* 2014;134:189–96.
- [39] Yang GY, Taboada S, Liao J. Inflammatory bowel disease: a model of chronic inflammation-induced cancer. *Methods in Molecular Biology* 2009;511:193–233.
- [40] Becker C, Fantini MC, Wirtz S, et al. IL-6 signaling promotes tumor growth in colorectal cancer. *Cell Cycle* 2005;4:217–20.
- [41] Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. *Immunity* 2004;21:491–501.
- [42] Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. *Cancer Cell* 2009;15:103–13.
- [43] Mitsuyama K, Matsumoto S, Rose-John S, et al. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. *Gut* 2006;55:1263–9.
- [44] Li Y, de Haar C, Chen M, et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. *Gut* 2010;59:227–35.
- [45] Matsumoto S, Hara T, Mitsuyama K, et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. *The Journal of Immunology* 2010;184:1543–51.
- [46] Agoff SN, Brentnall TA, Crispin DA, et al. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. *American Journal of Pathology* 2000;157:737–45.
- [47] Federico A, Morgillo F, Tuccillo C, et al. Chronic inflammation and oxidative stress in human carcinogenesis. *International Journal of Cancer* 2007;121:2381–6.
- [48] Meira LB, Bugni JM, Green SL, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. *The Journal of Clinical Investigation* 2008;118:2516–25.
- [49] Mangerich A, Knutson CG, Parry NM, et al. Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer. *Proceedings of the National Academy of Sciences of the United States of America* 2012;109:E1820–9.
- [50] Kado S, Uchida K, Funabashi H, et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. *Cancer Research* 2001;61:2395–8.
- [51] Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. *Cell* 2009;139:485–98.
- [52] Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. *Nature* 2008;453:620–5.
- [53] Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. *Nature Reviews Immunology* 2009;9:313–23.
- [54] Schottelius AJ, Mayo MW, Sartor RB, et al. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. *The Journal of Biological Chemistry* 1999;274:31868–74.
- [55] Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. *The Journal of Clinical Investigation* 1996;98:1010–20.
- [56] Suzuki H, Harpaz N, Tarmin L, et al. Microsatellite instability in ulcerative colitis-associated colorectal dysplasias and cancers. *Cancer Research* 1994;54:4841–4.
- [57] O'Sullivan JN, Bronner MP, Brentnall TA, et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. *Nature Genetics* 2002;32:280–4.
- [58] Risques RA, Lai LA, Brentnall TA, et al. Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. *Gastroenterology* 2008;135:410–8.
- [59] Burner GC, Rabinovitch PS, Haggitt RC, et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. *Gastroenterology* 1992;103:1602–10.
- [60] Chaubert P, Benhattar J, Saraga E, et al. K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. *American Journal of Pathology* 1994;144:767–75.
- [61] Holzmann K, Klump B, Borchard F, et al. Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis. *International Journal of Cancer* 1998;76:1–6.
- [62] Yin J, Harpaz N, Tong Y, et al. P53 point mutations in dysplastic and cancerous ulcerative colitis lesions. *Gastroenterology* 1993;104:1633–9.
- [63] Greenwald BD, Harpaz N, Yin J, et al. Loss of heterozygosity affecting the p53, Rb, and mcc/apc tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis. *Cancer Research* 1992;52:741–5.
- [64] Harpaz N, Peck AL, Yin J, et al. P53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. *Human Pathology* 1994;25:1069–74.
- [65] Parenti AR, Rugge M, Frizzera E, et al. P53 overexpression in the multistep process of esophageal carcinogenesis. *The American Journal of Surgical Pathology* 1995;19:1418–22.
- [66] Hussain SP, Amstad P, Raja K, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. *Cancer Research* 2000;60:3333–7.
- [67] Cooks T, Pateras IS, Tarcic O, et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. *Cancer Cell* 2013;23:634–46.
- [68] Tarmin L, Yin J, Harpaz N, et al. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. *Cancer Research* 1995;55:2035–8.
- [69] Fogt F, Vortmeyer AO, Goldman H, et al. Comparison of genetic alterations in colonic adenoma and ulcerative colitis-associated dysplasia and carcinoma. *Human Pathology* 1998;29:131–6.
- [70] Umetani N, Sasaki S, Watanabe T, et al. Genetic alterations in ulcerative colitis-associated neoplasia focusing on APC, K-ras gene and microsatellite instability. *Japanese Journal of Cancer Research* 1999;90:1081–7.
- [71] Redston MS, Papadopoulos N, Caldas C, et al. Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. *Gastroenterology* 1995;108:383–92.
- [72] Burner GC, Levine DS, Kulander BG, et al. c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. *Gastroenterology* 1990;99:416–20.
- [73] Bell SM, Kelly SA, Hoyle JA, et al. c-Ki-ras gene mutations in dysplasia and carcinomas complicating ulcerative colitis. *British Journal of Cancer* 1991;64:174–8.
- [74] Robles AI, Traverso G, Zhang M, et al. Whole-exome Sequencing analyses of inflammatory bowel disease-associated colorectal cancers. *Gastroenterology* 2016;150:931–43.
- [75] Hsieh CJ, Klump B, Holzmann K, et al. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. *Cancer Research* 1998;58:3942–5.
- [76] Matsumura S, Oue N, Ito R, et al. The promoter methylation status of the DNA repair gene O6-methylguanine-DNA methyltransferase in ulcerative colitis. *Virchows Archiv* 2003;443:518–23.
- [77] Fujiwara I, Yashiro M, Kubo N, et al. Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway. *Diseases of the Colon & Rectum* 2008;51:1387–94.
- [78] Fleisher AS, Esteller M, Harpaz N, et al. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. *Cancer Research* 2000;60:4864–8.
- [79] Katsurano M, Niwa T, Yasui Y, et al. Early-stage formation of an epigenetic field defect in a mouse colitis model, and non-essential roles of T- and B-cells in DNA methylation induction. *Oncogene* 2012;31:342–51.
- [80] Konishi K, Shen L, Wang S, et al. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. *Gastroenterology* 2007;132:1254–60.
- [81] Sanchez JA, DeJulius KL, Bronner M, et al. Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer. *Inflammatory Bowel Diseases* 2011;17:1966–70.
- [82] Fassan M, Croce CM, Rugge M. miRNAs in precancerous lesions of the gastrointestinal tract. *World Journal of Gastroenterology* 2011;17:5231–9.
- [83] D'Angelo E, Vicentini C, Agostini M, et al. MicroRNAs as tools and effectors for patient treatment in gastrointestinal carcinogenesis. *Current Drug Targets* 2015;16:383–92.
- [84] Fassan M, Baffa R. MicroRNAs and targeted therapy: small molecules of unlimited potentials. *Current Opinion in Genetics & Development* 2013;23:75–7.
- [85] Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. *Gastroenterology* 2008;135:1624–5, e24.
- [86] Valeri N, Braconi C, Gasparini P, et al. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. *Cancer Cell* 2014;25:469–83.
- [87] Ludwig K, Fassan M, Mescoli C, et al. PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis. *Virchows Archiv* 2013;462:57–63.
- [88] Paraskevi A, Theodoropoulos G, Papaconstantinou I, et al. Circulating MicroRNA in inflammatory bowel disease. *Journal of Crohn's and Colitis* 2012;6:900–4.
- [89] Fisher K, Lin J. MicroRNA in inflammatory bowel disease: translational research and clinical implication. *World Journal of Gastroenterology* 2015;21:12274–82.